Candriam SCA’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $77.6M | Sell |
|
|||||
|
2025
Q1 | $67.5M | Sell |
|
|||||
|
2024
Q4 | $66.5M | Sell |
|
|||||
|
2024
Q3 | $96.7M | Buy |
|
|||||
|
2024
Q2 | $85.3M | Buy |
|
|||||
|
2024
Q1 | $47.4M | Buy |
|
|||||
|
2023
Q4 | $47.9M | Sell |
|
|||||
|
2023
Q3 | $58.2M | Buy |
|
|||||
|
2023
Q2 | $60.6M | Sell |
|
|||||
|
2023
Q1 | $60.5M | Buy |
|
|||||
|
2022
Q4 | $76.2M | Sell |
|
|||||
|
2022
Q3 | $70.7M | Buy |
|
|||||
|
2022
Q2 | $50.1M | Buy |
|
|||||
|
2022
Q1 | $49.6M | Buy |
|
|||||
|
2021
Q4 | $40.8M | Buy |
|
|||||
|
2021
Q3 | $25.1M | Sell |
|
|||||
|
2021
Q2 | $29.6M | Buy |
|
|||||
|
2021
Q1 | $20.3M | Hold |
|
|||||
|
2020
Q4 | $21.1M | Sell |
|
|||||
|
2020
Q3 | $24.4M | Hold |
|
|||||
|
2020
Q2 | $24.8M | Sell |
|
|||||
|
2020
Q1 | $21.5M | Hold |
|
|||||
|
2019
Q4 | $22M | Buy |
|
|||||
|
2019
Q3 | $15.3M | Sell |
|
|||||
|
2019
Q2 | $27.6M | Buy |
|
|||||
|
2019
Q1 | $26.6M | Hold |
|
|||||
|
2018
Q4 | $20.8M | Buy |
|
|||||
|
2018
Q3 | $20.2M | Buy |
|
|||||
|
2018
Q2 | $11.7M | Buy |
|
|||||
|
2018
Q1 | $11.3M | Buy |
|
|||||
|
2017
Q4 | $12.1M | Sell |
|
|||||
|
2017
Q3 | $14.1M | Buy |
|
|||||
|
2017
Q2 | $6.7M | Buy |
|
|||||
|
2017
Q1 | $3.43M | Buy |
|
|||||
|
2016
Q4 | $2.25M | Hold |
|
|||||
|
2016
Q3 | $4.07M | Sell |
|
|||||
|
2016
Q2 | $4.05M | Buy |
|
|||||
|
2016
Q1 | $3.81M | Buy |
|
|||||
|
2015
Q4 | $5.37M | Sell |
|
|||||
|
2015
Q3 | $5.01M | Sell |
|
|||||
|
2015
Q2 | $10.7M | Buy |
|
|||||
|
2015
Q1 | $2.82M | Sell |
|
|||||
|
2014
Q4 | $3.2M | Buy |
|